Cardiovascular Risk Monitoring and Management in RA Patients

Initial Cardiovascular Risk Assessment

• The European Society of Cardiology recommends applying a 1.5 multiplication factor to standard risk calculators if the patient meets two of the three criteria: disease duration >10 years, RF or anti-CCP antibody positivity, or presence of extra-articular manifestations 1, 2, 3
• The American College of Rheumatology suggests performing a comprehensive CV risk evaluation before disease progression or treatment changes complicate the picture 3, 4
• Measure total cholesterol and HDL cholesterol to calculate the TC/HDL ratio, which is the most important lipid parameter in RA 2, 4, 5

CV Risk Factor Optimization

• The European Heart Journal recommends targeting LDL-C <3.0 mmol/L (115 mg/dL) for all RA patients, even those in lower risk categories 10
• Statins are first-line therapy for lipid management, with atorvastatin or rosuvastatin preferred due to their anti-inflammatory effects 1, 7, 10
• ACE inhibitors or angiotensin II blockers are preferred antihypertensives due to potential anti-inflammatory properties 1, 7, 6

Lifestyle Interventions

• Smoking cessation is mandatory, with referral to evidence-based cessation programs even if prior attempts failed 2, 7, 5
• Regular structured exercise reduces inflammation and improves CV risk profile 5
• A healthy diet emphasizing Mediterranean pattern is recommended 5

Coordination of Care

• The rheumatologist should take the lead on ensuring CV risk management is performed correctly, at least until CV prevention becomes well-integrated into routine RA care 8, 9
• Collaborate with primary care physicians or cardiologists for actual CV risk factor treatment according to national guidelines 1, 2, 7